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Background: De novo acute myeloid leukemia (AML) with concurrent DNMT3A, FLT3 and NPM1 mutations
(AMLDNMT3A/FLT3/NPM1) has been suggested to represent a unique AML subset on the basis of integrative genomic
analysis, but the clinical features of such patients have not been characterized systematically.
Methods: We assessed the features of patients (n = 178) harboring mutations in DNMT3A, FLT3 and/or NPM1,
including an index group of AMLDNMT3A/FLT3/NPM1 patients.
Results: Patients with AMLDNMT3A/FLT3/NPM1 (n = 35) were significantly younger (median, 56.0 vs. 62.0 years; p = 0.025),
mostly women (65.7% vs. 46.9%; p = 0.045), and presented with a higher percentage of bone marrow blasts (p < 0.001) and
normal cytogenetics (p = 0.024) in comparison to patients within other mutation groups in this study. Among patients
<60 years old, those with AMLDNMT3A/FLT3/NPM1 had a shorter event-free survival (EFS) (p = 0.047). DNMT3A mutations and not
FLT3 or NPM1 mutations were independently associated with overall survival (OS) (p = 0.026). Within mutation subgroups,
patients with AMLDNMT3A/NPM1 had a significantly shorter OS compared to those with AMLFLT3-ITD/NPM1 (p = 0.047)
suggesting that the adverse impact of DNMT3A mutations is more pronounced than that of FLT3-ITD among patients with
NPM1 mutation.
Conclusions: DNMT3A has a significant dominant effect on the clinical features and outcomes of de novo AML patients
with concurrent DNMT3A, FLT3 and NPM1 mutations.
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DNMT3A, FLT3, and NPM1 mutations are among the
most common genomic alterations in de novo acute
myeloid leukemia (AML) and play a key role in the
pathogenesis and evolution of the disease, particularly in
the absence of AML-associated recurrent cytogenetic
abnormalities [1,2]. DNMT3A encodes a DNA methyl-
transferase that catalyzes the addition of a methyl group
to cytosine residues in CpG islands resulting in reduced
expression of downstream genes. DNMT3A mutations,* Correspondence: jkhoury@mdanderson.org
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in patients with intermediate risk cytogenetics [1-4].
Mutations resulting in constitutive FLT3 activation in-
clude internal tandem duplication (FLT3-ITD) mutations
and tyrosine kinase domain (FLT3-TKD) point mutations;
FLT3-ITD in particular is a known adverse prognostic in-
dicator in AML patients [2,5-13]. NPM1 mutations are
generally associated with more favorable outcomes in
cytogenetically normal (CN)-AML in the absence of
FLT3-ITD [6,14].
Integrative genomic analysis of de novo AML by The
Cancer Genome Atlas (TCGA) consortium recently
identified a subset of AML patients in which DNMT3A,
FLT3, and NPM1 mutations coexist at a higher fre-
quency than would be expected for a chance occurrencel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to as AMLDNMT3A/FLT3/NPM1) seems to have unique
characteristics at the mRNA, miRNA, and epigenetic
levels [1], its clinical features are not known. However,
whereas the clinical implications of FLT3 and NPM1
mutations in de novo AML are largely well established,
the impact of DNMT3A mutations on NPM1 and/or
FLT3 mutations remains poorly understood especially in
patients with AMLDNMT3A/FLT3/NPM1 [15,16]. Several stud-
ies have suggested that the presence of DNMT3A muta-
tions in AML is associated with poor clinical outcomes
[3,4,17,18]. In one study, patients with AML harboring
both DNMT3A and FLT3-ITD mutations relapsed more
often than patients with either DNMT3A or FLT3-ITD
alone [19]. Yet, in other studies DNMT3A mutations were
not independently predictive of clinical outcomes in the
overall AML population or specific subgroups [2,15,19-21].
In this study, we assess the clinical and outcome char-
acteristics of patients with AMLDNMT3A/FLT3/NPM1 as an
index group and compare them to those with de novo
AML harboring other mutation combinations involving
DNMT3A, FLT3 and/or NPM1 to further elucidate the




The study group consisted of 178 de novo AML patients
with one, two, or three mutations involving the
DNMT3A, FLT3 and/or NPM1 genes. The composition
of the mutation subgroups is illustrated in Figure 1. The
MD Anderson Cancer Center (MDACC) group (n = 85)
consisted of 43 women and 42 men with a median age
of 64 years (range, 23 to 91 years). They included 18
patients with AMLDNMT3A/FLT3/NPM1 and 67 patientsFigure 1 Mutation subgroups of de novo acute myeloid leukemia inclwith the following mutations: FLT3 and NPM1
(AMLFLT3/NPM1, n = 22); NPM1 only (AMLNPM1, n = 15);
DNMT3A only (AMLDNMT3A, n = 13); DNMT3A and
FLT3 (AMLDNMT3A/FLT3, n = 8); DNMT3A and NPM1
(AMLDNMT3A/NPM1, n = 7); and, FLT3 only (AMLFLT3, n = 2).
The TCGA group (n = 93) consisted of 47 women and 46
men with a median age of 58 years (range, 21 to 83 years).
They included 17 patients with AMLDNMT3A/FLT3/NPM1
and 76 patients with the following mutations: FLT3 and
NPM1 (AMLFLT3/NPM1, n = 12); NPM1 only (AMLNPM1,
n = 14); DNMT3A only (AMLDNMT3A, n = 19); DNMT3A
and FLT3 (AMLDNMT3A/FLT3, n = 4); DNMT3A and NPM1
(AMLDNMT3A/NPM1, n = 10); and, FLT3 only (AMLFLT3,
n = 17).
Characteristics of AMLDNMT3A/FLT3/NPM1
The characteristics of patients within mutation subgroups
are summarized in Table 1. Since patients with concomitant
mutations in DNMT3A, FLT3 and NPM1 (index group) had
been reported to possibly represent a distinctive genomic
subset of de novo AML with unique characteristics at the
mRNA, miRNA, and epigenetic levels [1], their features
were first compared to those of patients in other mutation
groups. Patients with AMLDNMT3A/FLT3/NPM1 were signifi-
cantly younger (median 56.0 vs. 62.0 years; p = 0.025). Most
were women (65.7% vs. 46.9%; p = 0.045) who presented
with a heavy disease burden, namely an elevated WBC
(50.9 vs. 19.0 × 103/μL; p = 0.006) and BM blast counts
(83.5% vs. 71.0%, p < 0.001).
Morphologically, AMLDNMT3A/FLT3/NPM1 tended to be
associated with myelomonocytic blast morphology, which
corresponds to the M4 and M5 categories in the French
American British (FAB) classification [22]. Among 32
AMLDNMT3A/FLT3/NPM1 cases with FAB classification data,
10 (31%) were M4; 8 (25%) were M5; 6 (19%) were M1;uded in the study.
Table 1 Demographic, clinical and laboratory characteristics of patients in the study group
Variable AMLDNMT3A/FLT3/NPM1 Other* P-value
Age (years) Median 56.00 62.00 0.025
Range 29-81 21-91
Sex Female (%) 23 (65.7) 67 (46.9) 0.045
Male (%) 12 (34.3) 76 (53.1)
BM Blast % (range) Median 83.5 (29-98) 71.0 (20-99) <0.001
Hemoglobin g/dL (range) Median 9.6 (6-13) 9.3 (6-14.3) 0.683
WBC 103/μL (range) Median 50.9 (0.1-298) 19.0 (0.3-297) 0.006
Monocytes 103/μL (range) Median 4.0 (0-76) 5.0 (0-73) 0.960
Platelets 103/μL (range) Median 45.0 (7-218) 50.0 (8-1069) 0.397
PB Blast % (range) Median 46.0 (0-99) 23.0 (0-99) 0.191
CG Risk Group %† Intermediate 91.4 80.4 0.168
Poor 2.9 14.0
CN-AML% 87.5 67.4 0.024
*Includes: All mutation groups other than AMLDNMT3A/FLT3/NPM1.
Abbreviations: AML acute myeloid leukemia, BM bone marrow, PB peripheral blood, WBC white blood cell count, CG cytogenetic, CN-AML cytogenetically normal AML.
Bold font indicates parameters with significant differences between groups.
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fractory anemia with excess blasts in transformation.
None of these cases displayed sufficient dysplasia in
background hematopoietic elements to warrant classifi-
cation as AML with myelodysplasia-related changes. In
most cases blasts showed “cup-like” nuclear morph-
ology, which had been described previously in associ-
ation with FLT3-ITD and NPM1 mutations [23,24].
Namely, blasts with cup-like nuclear morphology were
identified in 17/18 (94.4%) AMLDNMT3A/FLT3/NPM1 cases
and comprised a variable subset of total blasts, ranging
from 3-53% (median 9%; mean 16.1%). In 10/18 (55.5%)
cases, such blasts comprised >10% of total blasts.
By flow cytometry immunophenotyping (MDACC group),
all AMLDNMT3A/FLT3/NPM1 had a definite myeloid immu-
nophenotype. In all cases, blasts were positive for CD13,
CD33, and CD123 and negative for surface and cytoplas-
mic CD3 expression. Myeloperoxidase expression was de-
tected in 11/14 (78.6%) cases. Blasts were positive for
CD34 in 13/18 (72.2%) cases. In accordance with myelo-
monocytic morphology, blasts expressed one or more
monocyte-associated antigens (CD4, CD14, CD64) in 11/
18 (61.1%) cases. In one case, myeloid blasts co-expressed
the B-cell marker CD19. (Additional file 1: Figure S1).
A significant association was observed between
AMLDNMT3A/FLT3/NPM1 and diploid karyotype (CN-AML)
(p = 0.024). Among 33 AMLDNMT3A/FLT3/NPM1 patients
with available cytogenetics data, 32 (97%) had intermedi-
ate-risk cytogenetics and included 28 (85%) CN-AML.
Only 1 (3%) patient had poor-risk cytogenetics. Notably,
none of the patients had recurrent AML-associated cyto-
genetic abnormalities.A summary of mutations in genes assessed in both
the MDACC and TCGA groups is provided in Figure 2a.
All DNMT3A variants detected in patients with
AMLDNMT3A/FLT3/NPM1 were missense substitutions in
exon 23, and most involved codon 882 resulting in the
substitution of arginine by histidine (14/35; 40%) or cyst-
eine (14/35; 40%). Mutations in other codons - 882 (argin-
ine > serine), 901 (leucine > proline), 874 (tyrosine-stop),
803 (arginine to serine), 855 (lysine to threonine) and 723
(frameshift) - were detected with less frequency. (Figure 2b)
(Additional file 2: Table S1).
FLT3 mutations in the AMLDNMT3A/FLT3/NPM1 group in-
cluded FLT3-ITD in 24/35 (69%), FLT3-TKDD835 in 9/35
(26%), and simultaneous FLT3-ITD/TKDD835 mutations in
2/35 (6%). There was no significant difference in FLT3
mutation types between the AMLDNMT3A/FLT3/NPM1 and
the other mutations groups (p = 0.108) (Additional file 2:
Table S2). NPM1 mutations uniformly involved exon 12
in all MDACC cases. Other mutations observed in
AMLDNMT3A/FLT3/NPM1 included IDH1 (17.1%), NRAS
(8.5%), KIT (2.8%), IDH2 (2.8%), CEBPA (2.8%) and
NOTCH1 (2.8%). None of the cases had mutations
in TP53.
To assess the relative dominance of mutations in in-
dividual cases within the AMLDNMT3A/FLT3/NPM1 group,
we estimated the variant frequency of each of the mu-
tant DNMT3A, FLT3, and NPM1 alleles in a subset
MDACC samples and found them to be generally com-
mensurate, suggesting that they commonly co-occur
within a dominant clone (Figure 3). In addition, the es-
timated variant frequency suggested that these muta-
tions are heterozygous.
Figure 2 Schematic representation of mutations. (a) Mutation status of genes assessed in all patients in the study group. Each column represents an
individual case. The bottom rows represent, respectively, the cytogenetic risk group (CG) and mutation group (MG) per corresponding color designation.
Assessed genes in which mutations were not detected are not included in this diagram. Mutation detection techniques in the MDACC and TCGA groups
were different (see Methods section). (b) Distribution of genomic variants within DNMT3A detected in the study group. PWWP represents a region encoding
for a highly conserved proline-tryptophan-tryptophan-proline motif. ZNF represents the ADD (ATRX, DNMT3, and DNMT3L)-type zinc finger domain.
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Follow-up data was available for 84/85 patients in the
MDACC group with a median follow up of 11.8 months
(range, 0.6-69.0 months). Of these patients, 50/84 pre-
sented to our institution at diagnosis prior to induction
chemotherapy (4/50 with AMLDNMT3A/FLT3/NPM1), 9
presented with primary refractory disease (2/9 with
AMLDNMT3A/FLT3/NPM1), and 20 presented in relapse
(10/20 with AMLDNMT3A/FLT3/NPM1). An additional 5patients (2/5 with AMLDNMT3A/FLT3/NPM1) were in remis-
sion at the time of referral to our institution. Allogeneic
SCT therapy was administered to 25 patients (7/25 with
AMLDNMT3A/FLT3/NPM1) in the MDACC group. When the
actual last follow up date was considered, no difference in
OS was observed between those who received allo-SCT
and those who did not (p = 0.203); similarly, no differ-
ence in OS was observed between AMLDNMT3A/FLT3/NPM1
patients who received allo-SCT and those who did
not (p = 0.186). At last follow up, 32 MDACC patients
Figure 3 Estimated DNMT3A, FLT3, and NPM1 variant (allelic) frequencies in a subset of de novo acute myeloid leukemia samples
harboring all three mutations.
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portantly, there was no identifiable bias in survival out-
comes on the basis of therapy selection (high-intensity vs.
low-intensity, and “3 + 7” vs. “non-3 + 7”) for any of the
prognostic parameters assessed by univariate or multi-
variate modeling in the MDACC group. Survival data was
available for 87/93 patients in the TCGA group with a
median follow up of 9.2 months (range, 0.9-62.8 months).
At last follow up, 60 patients (13 AMLDNMT3A/FLT3/NPM1)
in the TCGA group were dead of disease, the majority
during first relapse.
Younger (<60 years) patients with AMLDNMT3A/FLT3/NPM1
had a significantly shorter EFS (p = 0.047) and a tendency
towards shorter OS (p = 0.095) compared to those in the
other mutation groups (Figure 4a-b). Although patients
with AMLDNMT3A/FLT3/NPM1 tended to have shorter OS
compared to those in the other mutation groups, the dif-
ference was not significant in the entire group as well as
within the CN-AML group (p = 0.211 and p = 0.209, re-
spectively). Importantly, there was no significant differ-
ence in OS among AMLDNMT3A/FLT3/NPM1 patients with
FLT3-ITD and FLT3-TKD mutations types (p = 0.822).
To begin understanding the differential clinical impact of
DNMT3A mutations relative to FLT3 and NPM1 on out-
comes in de novo AML, including AMLDNMT3A/FLT3/NPM1,
we then turned our attention to multivariate analysis. The
latter demonstrated that age (p = 0.019), DNMT3A muta-
tions (p = 0.026), IDH1 mutation (p = 0.002), and cytogen-
etics (poor-risk vs. intermediate/better-risk) (p = 0.018)
were independently associated with OS. Poor-risk cyto-
genetics followed by DNMT3A mutations were the stron-
gest unfavorable factors, while IDH1 mutation was
favorable (Table 2). The adverse effect of DNMT3Amutations (p = 0.039) persisted when only younger
(<60 years) patients were considered in multivariate ana-
lysis. To control for the impact of cytogenetics, we pro-
ceeded to assess OS and EFS as a function of DNMT3A
mutation status among patients with CN-AML. Indeed,
DNMT3A mutations within the CN-AML subset were as-
sociated with significantly shorter OS and EFS (p = 0.044
and p = 0.051, respectively). (Additional file 3: Figure S2A-
B) The adverse impact of DNMT3A mutations on OS was
particularly notable among CN-AML patients <60 years of
age (p = 0.014). These data suggest that in the absence of
high-risk cytogenetics, DNMT3A mutations exert an inde-
pendent impact on de novo AML outcomes including
those of the AMLDNMT3A/FLT3/NPM1 group.
We then asked whether the dominant effect of
DNMT3A mutations seen in AMLDNMT3A/FLT3/NPM1 is
observed in AML with either NPM1 or FLT3 mutations,
which are important factors in risk stratification particu-
larly for younger patients with CN-AML [26,27]. Not-
ably, among patients with NPM1 mutation, those with
CN-AMLNPM1/DNMT3A had significantly shorter OS and
EFS compared to those with CN-AMLNPM1 and wild-
type DNMT3A (p = 0.022 and p = 0.040, respectively).
These differences in OS and EFS were also observed
within the entire AML group (p = 0.017 and p = 0.025,
respectively) (Figure 4c-d). Importantly, the adverse im-
pact of DNMT3A mutations on OS among AMLNPM1
patients was particularly pronounced in those <60 years
of age, within both the entire group and the CN-AML
group (p = 0.008 and p = 0.014, respectively). Furthermore,
patients with CN-AMLDNMT3A/NPM1 had shorter OS
and EFS compared to those with CN-AMLFLT3-ITD/NPM1




















Figure 4 Survival analysis by mutation status. Overall survival (a) and event-free survival (b) of de novo acute myeloid leukemia patients younger
than 60 years of age with concomitant mutations in DNMT3A, FLT3, and NPM1 (AMLDNMT3A/FLT3/NPM1) in comparison to those within other mutation
subgroups in this study. Overall survival (c) and event-free survival (d) of patients with AML harboring NPM1 mutation in conjunction with wild-type
DNMT3A (NPM1 group) or mutant DNMT3A (NPM1/DNMT3A group). Overall survival (e) of patients with CN-AML harboring NPM1 mutations with
concomitant FLT3 (NPM1/FLT3 group) or DNMT3A (NPM1/DNMT3A group).
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TKD) cases were included (p = 0.054 and p = 0.051, re-
spectively) (Figure 4e) and suggests that the impact of
DNMT3A mutations is more pronounced than that of
FLT3 (ITD and TKD) in CN-AMLNPM1. Conversely,among all patients with DNMT3A, there was no signifi-
cant difference in OS or EFS between AMLDNMT3A/NPM1
and AMLDNMT3A/FLT3 (p = 0.301 and p = 0.989, respect-
ively), suggesting that the dominant effect of DNMT3A
mutations is not modulated by the presence of NPM1 or
Table 2 Multivariate analysis of the impact of demographic,
laboratory, and molecular parameters on overall survival in




Age 0.019 1.032 1.005 1.060
Sex 0.688 0.881 0.476 1.631
FLT3 mutation 0.222 1.521 0.775 2.985
NPM1 mutation 0.476 1.306 0.627 2.720
DNMT3A mutation 0.026 2.552 1.120 5.816
IDH 1 mutation 0.002 0.223 0.085 0.588
IDH 2 mutation† 0.134 0.407 0.125 1.320
Poor risk cytogenetics* 0.018 4.584 1.297 16.199
CN-AML 0.358 1.596 0.589 4.328
BM blast percentage 0.487 0.995 0.981 1.009
PB blast percentage 0.692 1.002 0.992 1.012
Hemoglobin 0.864 0.984 0.816 1.186
White blood count 0.640 1.002 0.995 1.008
†Include 17 cases with IDH2R140 and 2 with IDH2R172 [25].
*Poor-risk vs intermediate and better risk categories per National
Comprehensive Cancer Network guidelines (version 2.2013) [26].
Abbreviations: HR hazards ratio, CI confidence interval, BM bone marrow,
PB peripheral blood, CN-AML cytogenetically normal (diploid) acute myeloid
leukemia.
Bold font indicates parameters with significant impact on overall survival.
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for patients with AMLDNMT3A/FLT3/NPM1 (n = 35) to that of
patients with AMLFLT3/NPM1 (n = 34) we noticed that the
former group tended to have worse OS and EFS, al-
though the difference was not statistically significant
(Additional file 4: Figure S3).
Discussion
Integrative genomic analysis data from TCGA suggest
that AMLDNMT3A/FLT3/NPM1 is a unique disease subset
with distinctive features at the mRNA, miRNA, and epi-
genetic levels, but the clinical features and outcome
characteristics of this AML subset remain unknown. By
simultaneously harboring DNMT3A, FLT3 and NPM1
mutations, AMLDNMT3A/FLT3/NPM1 offers a unique ad-
vantage to study the differential impact of these genes in
AML. This is particularly important because although
the clinical implications of FLT3 and NPM1 mutations
in de novo AML have been well characterized, their
prognostic impact in the presence of concurrent
DNMT3A mutations has not been assessed systematic-
ally. Accordingly, we designed this study to investigate
the clinical and outcome characteristics of patients with
AMLDNMT3A/FLT3/NPM1 as an index group and compare
them to those with de novo AML harboring other muta-
tion combinations involving DNMT3A, FLT3 and/orNPM1. Since the incidence of AMLDNMT3A/FLT3/NPM1 is
low, cases seen at our institution were combined with
those in the TCGA data set to increase the statistical
power of our analysis. The inclusion of patients from
two different cohorts and the combination of MDACC
patients with untreated disease along with those who
presented in relapse or with persistent leukemia for stat-
istical purposes are acknowledged limitations of this
retrospective study. Notwithstanding, our data demonstrate
a significant association between AMLDNMT3A/FLT3/NPM1
and the following clinical features: young age, female gen-
der, diploid cytogenetics, poor EFS and OS particularly in
patients <60 years of age, and a heavy disease burden
manifested by elevated peripheral blood and bone marrow
blast counts. These features of AMLDNMT3A/FLT3/NPM1 are
reminiscent of the salient clinical attributes described
broadly for AML patients with DNMT3A mutations [1-4].
In the NCCN [26] and ELN [27] risk classification sys-
tems for AML, due importance is placed on NPM1 and
FLT3 but not DNMT3A mutations in CN-AML. In our
study group, patients with DNMT3A mutations had
worse outcomes than those with wild-type DNMT3A.
Hou et al. [28] and Ribeiro et al. [29] have similarly
demonstrated that DNMT3A mutations are independent
predictors of shorter OS in patients with de novo AML.
Shirarov et al. [30] also demonstrated in their study that
DNMT3A mutations were associated with worse out-
come including significantly shorter OS and EFS and are
an independent determinate of worse outcome in youn-
ger patients with CN-AML. In addition, recent data
demonstrate that DNMT3A mutation status has an im-
pact on therapy selection; in one study, patients with
DNMT3A mutations who were treated with high-dose
daunorubicin compared to standard-dose therapy were
shown to have longer OS [2].
Our findings suggest that in the absence of high-risk
cytogenetics, DNMT3A mutation status has an impact
on outcome in the presence of FLT3 and/or NPM1. In
this study group, mutant DNMT3A is associated with
adverse outcomes among CN-AML patients that have
NPM1 mutations. This effect appears more pronounced
than that of either FLT3-ITD or FLT3-TKD mutations
and is not mitigated by NPM1 or dependent on the pres-
ence of cytogenetic abnormalities. However, by current
risk stratification schemes CN-AMLDNMT3A/NPM1 pa-
tients would be regarded as a better/favorable risk group
whereas they likely should be reclassified in higher risk
categories. Along similar lines, Kihara et al suggested re-
cently that ELN risk stratification can be enhanced by
reassigning patients in the Favorable risk category to the
Intermediate-I group if they have DNMT3A mutations
[31]. Data from this study suggests that among patients
with de novo CN-AML, particularly those <60 years,
AMLDNMT3A/FLT3/NPM1 patients seem to have the worst
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and then those with AMLNPM1/DNMT3A.
Methods
Patient study group
This study was approved by the MDACC Institutional
Review Board. We searched our records for patients
with de novo AML and known mutation status for each
of DNMT3A, FLT3 and NPM1 who presented to our in-
stitution between 3/2009 and 12/2013. All patients met
the following study inclusion requirements: 1) positive
for mutations in DNMT3A, FLT3 and/or NPM1; 2)
18 years of age or older at diagnosis; 3) acute myeloid
leukemia diagnosis as defined in the World Health
Organization classification [32]. Patients with therapy-
related AML, history of myelodysplastic syndrome or
myeloproliferative neoplasms, and AML with t(15;17)
were excluded.
The demographic, laboratory, and clinical data on pa-
tients in the study group were collected by chart review
with emphasis on variables of demonstrated prognostic
utility in AML [33]. Flow cytometry immunophenotyp-
ing and cytogenetic analyses were performed as part of
routine clinical workup using previously described
techniques [34,35]. Patients were allocated to intermediate-
and high-risk cytogenetic risk groups per NCCN guide-
lines (version 2.2013) [26]. A detailed review of treatment
history for all patients in the MDACC study group was
undertaken, and patients were divided into high-intensity
(cytarabine and anthracycline based induction regimens,
further subdivided into “3 + 7” and “non-3 + 7”) and low-
intensity therapy groups.
As reported previously [1], the TCGA cohort consisted
of 200 adult patients with various subtypes of de novo
AML. To increase the statistical power of our analysis
and encompass a broader cohort of de novo AML pa-
tients, TCGA patients who had mutations in DNMT3A,
FLT3 and/or NPM1 were included in our study; those
with t(15;17) were excluded. Publicly available annotated
exome and whole-genome sequencing data as well as as-
sociated patient clinical data files were downloaded from
the TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga/)
at various time points between September 2013 and
January 2014. Patients were allocated to cytogenetic risk
groups as described above. Patients in the TCGA group
were treated per NCCN guidelines [1]. Patient enrollment
and utilization of data were conducted in accordance with
TCGA Human Subjects Protection and Data Access
Policies [36].
Mutation analysis
For NGS-based mutation screening of MDACC cases,
analysis of hotspot genomic areas was performed by
paired-end sequencing using the MiSeq (Illumina, SanDiego, CA) sequencer and the TruSeq Amplicon Cancer
Panel kit (Illumina) with 5 additional customized probe
pairs targeting DNMT3A (exon 23, codons 866-913),
XPO1, KLHL6, MYD88 and EZH2 as described previ-
ously [37]. Variant (allelic) frequency was estimated as
the percentage of variant reads over total reads at a spe-
cific allelic location. Matched germline DNA was not
available for comparison. FLT3 (ITD and TKD) and
NPM1 mutations were also screened using polymerase
chain reaction (PCR) followed by capillary electrophor-
esis on Genetic Analyzer (Applied Biosystems, Foster
City, CA), as described previously [38]. NGS-based mu-
tation analysis and testing for FLT3 and NPM1 status
are routinely performed on all patients with new onset
or relapsed acute leukemia at our institution irrespective
of their cytogenetic risk groups. The TCGA mutation
analysis data was derived from whole genome and ex-
ome NGS and analyzed alongside matched germline
DNA [1].
Statistical analysis
Categorical and continuous variables were analyzed
using Pearson Chi-square and Kruskal-Wallis rank sum
tests, respectively. Overall survival (OS) was estimated
by the Kaplan-Meier method using as a reference time
point the date of initial AML diagnosis until death from
any cause or date of last follow-up. Event-free survival
(EFS) represented the duration of disease between the
initial diagnosis and first relapse. No EFS data was avail-
able for TCGA patients. For MDACC patients who re-
ceived allogeneic hematopoietic stem cell transplant
(allo-SCT), the date of transplant was assigned as the
last follow-up date. Survival curves were compared by
the log rank test. Differences between two groups were
considered significant if p-values were <0.05 in a two-
tailed test. Multivariate analysis was performed by Cox
proportional regression model. Significant factors were
identified by Wald backward stepwise elimination.
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